APO Research
Talk to an analyst

APO RESEARCH · REPORT

23-Valent Pneumococcal Polysaccharide Vaccine

23-Valent Pneumococcal Polysaccharide Vaccine is a vaccine product category defined by its pneumococcal antigen composition and formulation.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.

The commercial boundary

The selected edition describes a market scope. Product approvals, labelled use and clinical acceptance require their own evidence; neither report segmentation nor an illustrative image establishes medical suitability.

Which antigen composition and formulation define the vaccine?

Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.

Selected research

Market Outlook & Growth Opportunities

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026196 pages

Choose your research edition.

Industry Research23-Valent Pneumococcal Polysaccharide Vaccine Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

The major players in global 23-Valent Pneumococcal Polysaccharide Vaccine market include MSD, Sanofipasteur, etc. The top 2 players occupy about 80% shares of the global market. North America and Europe are main markets, they occupy about 50% of the global market. Single Dose Vial is the main type, with a share about 60%. For Children (2-10) is the main application, which holds a share about 40%.

Read the full market overview

This report provides an overview of the global 23-Valent Pneumococcal Polysaccharide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of 23-Valent Pneumococcal Polysaccharide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents 23-Valent Pneumococcal Polysaccharide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the 23-Valent Pneumococcal Polysaccharide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Company

MSD

Sanofipasteur

CDIBP

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Type

Single Dose Vial

Pre-filled Syringe

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Application

For Children (2-10)

For Person (10-64)

For The Old (Above or equal to 65)

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global 23-Valent Pneumococcal Polysaccharide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions 23-Valent Pneumococcal Polysaccharide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify 23-Valent Pneumococcal Polysaccharide Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze 23-Valent Pneumococcal Polysaccharide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 23-Valent Pneumococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of 23-Valent Pneumococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 23-Valent Pneumococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the 23-Valent Pneumococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global 23-Valent Pneumococcal Polysaccharide Vaccine industry.

Chapter 3: Detailed analysis of 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of 23-Valent Pneumococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of 23-Valent Pneumococcal Polysaccharide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends Table 2. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers Table 3. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges Table 4. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints Table 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Company (2021-2026) Table 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Company (K Dose) & (2021-2026) Table 8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price (US$/Dose) of Company (2021-2026) Table 10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Company, Product Type & Application Table 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global 23-Valent Pneumococcal Polysaccharide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Single Dose Vial Table 18. Significant Companies of Pre-filled Syringe Table 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Dose) Table 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021-2026) & (K Dose) Table 21. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2027-2032) & (K Dose) Table 22. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2026) Table 28. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of For Children (2-10) Table 30. Significant Companies of For Person (10-64) Table 31. Significant Companies of For The Old (Above or equal to 65) Table 32. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Dose) Table 33. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021-2026) & (K Dose) Table 34. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2027-2032) & (K Dose) Table 35. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2026) Table 41. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2027-2032) Table 42. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Dose) Table 43. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (K Dose) Table 44. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 45. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (K Dose) Table 46. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 47. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Region (2021-2026) Table 50. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Region (2027-2032) Table 52. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Average Price (US$/Dose) by Region (2021-2026) Table 53. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Average Price (US$/Dose) by Region (2027-2032) Table 54. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Dose) Table 55. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 57. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2026) Table 58. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 59. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2027-2032) Table 60. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Market Share by Country (2027-2032) Table 64. MSD Company Information Table 65. MSD Business Overview Table 66. MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 67. MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 68. MSD Recent Development Table 69. Sanofipasteur Company Information Table 70. Sanofipasteur Business Overview Table 71. Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 72. Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 73. Sanofipasteur Recent Development Table 74. CDIBP Company Information Table 75. CDIBP Business Overview Table 76. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 77. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 78. CDIBP Recent Development Table 79. Key Raw Materials Table 80. Raw Materials Key Suppliers Table 81. 23-Valent Pneumococcal Polysaccharide Vaccine Distributors List Table 82. 23-Valent Pneumococcal Polysaccharide Vaccine Customers List Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. 23-Valent Pneumococcal Polysaccharide Vaccine Product Image Figure 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (2021-2032) & (K Dose) Figure 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Average Price (US$/Dose) & (2021-2032) Figure 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Single Dose Vial Image Figure 10. Pre-filled Syringe Image Figure 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Dose) Figure 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032) Figure 17. For Children (2-10) Image Figure 18. For Person (10-64) Image Figure 19. For The Old (Above or equal to 65) Image Figure 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Dose) Figure 21. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Dose) Figure 27. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. 23-Valent Pneumococcal Polysaccharide Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Single Dose Vial
  • Pre-filled Syringe
Applications
  • For Children (2-10)
  • For Person (10-64)
  • For The Old (Above or equal to 65)
Companies covered
  • MSD
  • Sanofipasteur
  • CDIBP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 23-Valent Pneumococcal Polysaccharide Vaccine Market Dynamics
  1. 2.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends
  2. 2.2 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers
  3. 2.3 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints
3 23-Valent Pneumococcal Polysaccharide Vaccine Market by Company
  1. 3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Company Ranking (2024-2026)
  6. 3.6 Global 23-Valent Pneumococcal Polysaccharide Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global 23-Valent Pneumococcal Polysaccharide Vaccine Company Product Type and Application
  8. 3.8 Global 23-Valent Pneumococcal Polysaccharide Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 23-Valent Pneumococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 23-Valent Pneumococcal Polysaccharide Vaccine Market by Type
  1. 4.1 23-Valent Pneumococcal Polysaccharide Vaccine Type Introduction
  2. 4.1.1 Single Dose Vial
  3. 4.1.2 Pre-filled Syringe
  4. 4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type
  5. 4.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type
  9. 4.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032)
5 23-Valent Pneumococcal Polysaccharide Vaccine Market by Application
  1. 5.1 23-Valent Pneumococcal Polysaccharide Vaccine Application Introduction
  2. 5.1.1 For Children (2-10)
  3. 5.1.2 For Person (10-64)
  4. 5.1.3 For The Old (Above or equal to 65)
  5. 5.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application
  6. 5.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application
  10. 5.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032)
6 23-Valent Pneumococcal Polysaccharide Vaccine Regional Sales and Value Analysis
  1. 6.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2027-2032)
  5. 6.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
7 23-Valent Pneumococcal Polysaccharide Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032)
  6. 7.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 MSD
  2. 8.1.1 MSD Company Information
  3. 8.1.2 MSD Business Overview
  4. 8.1.3 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  6. 8.1.5 MSD Recent Developments
  7. 8.2 Sanofipasteur
  8. 8.2.1 Sanofipasteur Company Information
  9. 8.2.2 Sanofipasteur Business Overview
  10. 8.2.3 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  12. 8.2.5 Sanofipasteur Recent Developments
  13. 8.3 CDIBP
  14. 8.3.1 CDIBP Company Information
  15. 8.3.2 CDIBP Business Overview
  16. 8.3.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  18. 8.3.5 CDIBP Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Analysis
  2. 9.1.1 23-Valent Pneumococcal Polysaccharide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 23-Valent Pneumococcal Polysaccharide Vaccine Sales Mode & Process
  6. 9.2 23-Valent Pneumococcal Polysaccharide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 23-Valent Pneumococcal Polysaccharide Vaccine Distributors
  9. 9.2.3 23-Valent Pneumococcal Polysaccharide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst